Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16413295 | 1.00 | OPRK1 (0.52) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16413208 | 0.89 | OPRK1 (0.58) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16413209 | 0.89 | OPRK1 (0.58) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16412980 | 0.87 | MAPT (0.40) | MAPTTP53 | |
| SCHEMBL16412977 | 0.87 | MAPT (0.40) | MAPTTP53 | |
| SCHEMBL20554975 | 0.87 | OPRK1 (0.65) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16413292 | 0.87 | OPRK1 (0.65) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16412570 | 0.86 | OPRK1 (0.58) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16412567 | 0.86 | OPRK1 (0.58) | OPRK1CYP2D6CYP3A4TSHRCYP1A2 | |
| SCHEMBL16412403 | 0.74 | HRH3 (0.42) | MAPTALDH1A1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | claimed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | claimed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | claimed |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885CYP2D6 657/4885CYP3A4 734/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885CYP2D6 641/4885CYP3A4 716/4885 |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | OPRK1, OPRL1, OPRD1 | OPRK1 1/4885CYP2D6 641/4885CYP3A4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.